Abstract
This study investigates a dual-acting drug delivery system using naringenin (NAR) as a folate receptor ligand to enhance intestinal uptake and encapsulated NAR for combating inflammation. The dual-acting systems were tested in vitro on cisplatin-induced human kidney-2 cells and in vivo in a mouse model of cisplatin-induced acute kidney injury (AKI). NAR-loaded passive nanoparticles [P2Ns(NAR)] and dual-acting systems [P2Ns-NAR(NAR)] showed notable advantages over unformulated NAR, reducing the required dose by up to 57 and 79%, respectively. These nanoparticles modulated immune responses, restored T cell function, and shifted macrophage polarization from proinflammatory M1 to tissue-repairing M2. In addition, P2Ns-NAR(NAR) alleviated AKI by reducing fibrosis and lowering Toll-like receptor 4 and nuclear factor κB levels in the kidneys. Notably, P2Ns-NAR(NAR) outperformed other formulations, providing a 50% lower effective dose. This study emphasizes the potential of NAR to overcome intestinal barriers and highlights the importance of polymer functionality in delivering effective treatments for inflammatory diseases.